Kate also has considerable experience evaluating the strengths and weaknesses of patent portfolios in connection with acquisitions. She understands the interplay of how patent exclusivity and non-patent exclusivity, such as regulatory law, impact the value of an acquisition. As a result, Kate frequently serves as outside patent counsel to branded and generic pharmaceutical companies, life science companies, and chemical companies in acquisitions involving products ranging from multimillion dollar annual sales to multibillion dollar annual sales.

Kate has worked on a range of technologies including animal feed supplements and additives, human nutritional supplements, nucleic acid chemistry, protein chemistry including recombinant protein production and purification, carbohydrate chemistry, combinatorial chemistry, immunology, vaccines, engineered tissues for use as vasculature or cartilage replacement, stem cells, contrast agents for use in MRI and optimal imaging, bioactive conductive polymers, microalgae for biofuels, high throughput screening methods, and on a wide variety of pharmaceutical products that include small organic molecules and peptides for treating pain, inflammation, high blood pressure, blood coagulation, cancer and several other indications or disease states.